about
Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies.Cardioprotection for percutaneous coronary intervention--reperfusion quality as well as quantity.Optical Coherence Tomography Guided Percutaneous Coronary Intervention.Remote Ischemic Conditioning in Elective PCI?Implantation of bioresorbable vascular scaffolds following acute coronary syndrome is associated with reduced early neointimal growth and strut coverage.Direct stenting is an independent predictor of improved survival in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction.Stunning and Right Ventricular Dysfunction Is Induced by Coronary Balloon Occlusion and Rapid Pacing in Humans: Insights From Right Ventricular Conductance Catheter Studies.Prediction of postpercutaneous coronary intervention myocardial infarction: insights from intravascular imaging, coronary flow, and biomarker evaluation.Anatomical plaque and vessel characteristics are associated with hemodynamic indices including fractional flow reserve and coronary flow reserve: A prospective exploratory intravascular ultrasound analysis.Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a single-center experienceGLP-1 Is a Coronary Artery Vasodilator in HumansGlucagon-Like Peptide-1-Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon OcclusionPatent Foramen Ovale Closure in 2019Functional polymorphism in ABCA1 influences age of symptom onset in coronary artery disease patientsLetter in response to cardioprotection with melatonin in the acute myocardial infarction: Awaiting results of MARIA trial?Letter by Giblett and Hoole regarding article, "Remote ischemic postconditioning during percutaneous coronary interventions: remote ischemic postconditioning-percutaneous coronary intervention randomized trial"Rapid Pacing-Induced Right Ventricular Dysfunction Is Evident After Balloon-Expandable Transfemoral Aortic Valve ReplacementEarly disarticulation of a bioresorbable vascular scaffold: an underreported consequence of repeat imagingLetter in response to glucagon-like peptide-1 mediates cardioprotection by remote ischaemic conditioningTranscatheter treatment of postinfarct ventricular septal defectsEffects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot StudyPercutaneous management of paravalvular leaksGlucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial IschemiaThe role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trialComparison of Routine Versus Selective Glycoprotein IIb/IIIa Inhibitors Usage in Primary Percutaneous Coronary Intervention (from the British Cardiovascular Interventional Society)Author Correction: Percutaneous management of paravalvular leaks
P50
Q37108395-53AC75DD-1AA6-443C-9089-06506090C669Q38277141-5ADBA6ED-EC52-4581-94D0-4BD354658C3EQ38619507-BE67B0E7-CF98-4811-A45F-D8D107A8A331Q39219871-FB47589F-CDA1-44C1-A6A2-0A10790A4CD5Q39472403-A7BBCC60-9EC2-48DC-8C45-A355270143BAQ45395792-A8410BF5-02D9-478F-9260-E51153ACAE3DQ47172272-B4CE947E-4C8B-4750-B850-145C9E15BB6CQ47640772-620E738F-7A3E-4298-AD9D-39FF1AF01438Q47895396-0EB4E445-558A-48E1-A4B5-ED748398C63BQ58095051-CB991FDE-4A45-4EA4-ACA9-B15D55ED2925Q63915302-29B7B624-D4FD-418A-A92F-590E2C2CD7D1Q64081775-45F1D0F0-7F1E-4E8E-831E-8DAD7F851C1FQ64242470-838926F9-BD0D-4DE4-851D-92CD2AF427A7Q80107783-91064F20-2079-45C7-8521-9F7CE154EA5EQ86854295-4B12F9F7-1245-4607-9E17-15AD3F37566AQ88109447-4C27E7D5-F7D4-4AE0-9858-55DAF7BCDE0BQ89296837-CBFC61C8-7C54-484F-8CB6-6853C78C1758Q89446328-A49AE41C-2042-4631-9CBF-1D424FE96E71Q89488136-44735F4C-8F14-4A98-B2C0-594F1E6FBCC3Q89946821-3E8FC183-63BB-4914-BF46-8F7608BC7FF0Q90832017-95BFC43C-7F02-411A-B50C-F52F22F532CFQ91117790-860264BE-18CC-4BAC-AD90-C4B75161D3F1Q91242765-CD6486E3-B0BE-4C07-83A4-B24889A611B9Q91654802-461DF3FE-C0CB-4E16-9584-DC457C071BFDQ92414852-862E8BFE-D3B0-470E-A9E4-1DFD3D329452Q92461183-44AF6A15-A81E-4CE1-8832-5254A2311CEB
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Joel Giblett
@en
Joel Giblett
@nl
type
label
Joel Giblett
@en
Joel Giblett
@nl
prefLabel
Joel Giblett
@en
Joel Giblett
@nl
P108
P108
P31
P496
0000-0001-8020-5433